drugset
drugset / Trial / NCT04024332

Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects

NCT04024332 ↗

Phase 1 Completed 16 enrolled Idorsia Pharmaceuticals Ltd.
Non-randomizedParallel-groupOpen-labelOther

Summary

Study of the way the body takes up, distributes, and gets rid of ACT-541468 in subjects with abnormal kidney function compared to healthy subjects

Timeline

Start
2019-09-24
Primary completion
2020-08-14
Completion
2020-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 25 mg Oral

Indications

impaired renal function disease